Bath & Body Works' stock slides 7% premarket after Q2 revenue falls short of estimates
Bath & Body Works Inc.'s stock (BBWI) tumbled 7% in premarket trade Wednesday, after the company, which was spun out of Victoria's Secret, missed sales estimates for its second quarter. The company posted net income of $99 million, or 43 cents a share, for the quarter, down from $120 million, or 52 cents a share, in the year-earlier period. Adjusted per-share earnings came to 40 cents, ahead of the 33 cent FactSet consensus. Sales fell to $1.559 billion from $1.618 billion a year ago, below the $1.564 billion FactSet consensus. Chief Executive Gina Boswell said the company's sales matched expectations and earnings benefited from a cost optimization and merchandise margin improvement program. The company is now expecting full-year adj. EPS to range from $2.80 to $3.10 and for sales to fall 1.5% to 3.5%. The FactSet consensus is for EPS of $3.04. The stock has fallen 17% in the year to date, while the S&P 500 has gained 14%.
-Ciara Linnane
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
08-23-23 0617ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom